(European Vascular Interventions and Therapeutic Innovation Network) at MRC Technology’s Centre for Therapeutics Discovery.
MRC Technology (MRCT) is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere. As a champion for human health, MRCT partners with academic, biotechnology, pharmaceutical and charity organisations to move promising medical research forward into viable and accessible patient treatments.
The MRC Technology’s Centre for Therapeutics Discovery (CTD) is inviting applications for one fixed-term (36 month) Early Stage Researcher (ESR) to work within the EVOluTION project, a Marie Skłodowska-Curie Innovative Training Network (ITN) in translational pharmacology and therapeutic innovation (see http://academicpositions.co.uk/ad/queen-mary-university-of-london/2016/marie-curie-11-phd-fellowships/89452) for details of all project positions; ESR10 is the specific placement at MRCT.) The Early Stage Researcher appointed will be based primarily within MRC Technology’s Centre for Therapeutics Discovery chemistry group at our new state of the art facilities at the Stevenage Bioscience Catalyst site north of London. MRC Technology’s CTD operates at the interface between academic research and the drug discovery industry. As one of the largest and most successful academic drug discovery centres in Europe, we take novel academic targets and generate lead stage small molecules and therapeutic antibodies for indications with unmet medical need. We have a proven track record in partnering our assets with pharma and biotech companies; four of our projects have led to approved drugs and we have a strong pipeline in development. Further details about CTD can be found at www.mrctechnology.org.
Please note there are strict eligibility requirements which apply to all Marie Skłodowska-Curie Early Stage Researchers. At the time of appointment, applicants must not have resided or carried out their main activity (work, studies, etc.) in the UK for more than 12 months in the three years immediately before appointment under the project; and shall also be in the first four years of their research careers at the time of appointment by the host organisation and have not been awarded a doctoral degree. For more information on Marie Skłodowska-Curie Innovative Training Networks (ITNs), please see: http://ec.europa.eu/mariecurieactions.
As part of the Marie Skłodowska-Curie ITN scheme, the selected candidate is expected to register for and work towards a PhD degree, with the aim of completing this within the fixed term of your appointment (36 months, full-time employment contract). Registration for a PhD will be through the William Harvey Research Institute, QMUL, the other UK based member of the EVOluTION consortium. You will also be expected to work closely with the other ESRs, at other participating institutions, to go on secondments at one or more of the EVOluTION participating institutions, and to participate in the Network-wide training program.
The title of the research programme for this ESR is ‘The use of chemical biology to evaluate targets associated with vascular inflammation: identification and targeted delivery of novel agents for targets’
MRCT CTD uses both small molecule and antibody therapeutic development expertise in prosecuting novel targets. Tool compounds from either approach or in combination such as antibody-drug conjugates will be critical to supporting the work in all the EVOluTION research groups. MRCT has world class computational expertise in protein and antibody modelling and in structure based drug design, and it will be through the application of such approaches that truly novel and innovative therapeutics may evolve. The successful candidate will hold a first degree qualification in synthetic chemistry or closely related discipline, and will have an interest in chemical biology. The goals of the project include:
– Synthesis of required probe compounds to support target validation across the network targets, including FPR2 and XOR
– Development of novel agonists and/or antagonists of targets of interest through application of computational supported structure based drug design
– Application of antibody drug conjugation technologies to support targeted delivery, selectivity enhancement and pharmacological stability of novel therapeutic agents.
Informal enquiries about the position should be addressed to: Dr Andy Merritt at firstname.lastname@example.org; +44 (0)20 8906 7236
Informal enquiries about the whole EVOluTION programme may be made to Annabelle Scott (EVOluTION Project Manager): email@example.com.
Interested applicants should submit their CV and covering letter to Recruitment@tech.mrc.ac.uk who can also provide a full job description for the post should you need further information.
Candidates must also be able to demonstrate their eligibility to work in the UK in accordance with the Immigration, Asylum and Nationality Act 2006. Where required this may include entry clearance or continued leave to remain under the Points Based Immigration Scheme.
You will be offered a salary plus mobility allowance and family allowance (if applicable) in line with the Marie Skłodowska-Curie Horizon 2020 requirements for Early Stage Researchers.
The closing date for the applications is 30 June 2016. Interviews are expected to be held in July in Stevenage. It is envisaged that post will commence between September and October 2016 for 36 months.